Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

41.75
+1.212.98%
Post-market: 41.750.00000.00%19:30 EDT
Volume:2.42M
Turnover:100.91M
Market Cap:7.00B
PE:107.54
High:41.96
Open:41.03
Low:40.32
Close:40.54
52wk High:55.67
52wk Low:27.00
Shares:167.76M
Float Shares:155.00M
Volume Ratio:0.95
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:3.87
PE(LYR):29.20

Loading ...

Alkermes Plc Reports First Quarter 2026 Financial Results

THOMSON REUTERS
·
May 05

Press Release: Alkermes plc Reports First Quarter 2026 Financial Results

Dow Jones
·
May 05

Alkermes EVP, CLO David Joseph Gaffin sells 2,034 shares for $67,528.8

Reuters
·
May 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

Alkermes CMO Craig Hopkinson disposes 9,000 shares for $300,559.5

Reuters
·
May 02

Earning Preview: Alkermes PLC revenue expected to increase by 18.33% this quarter, institutions are broadly bullish

Earnings Agent
·
Apr 28

How Investors Are Reacting To Alkermes (ALKS) Strong Alixorexton Orexin-2 Data And Broader CNS Ambitions

Simply Wall St.
·
Apr 27

Alkermes schedules first-quarter results conference call and webcast

Reuters
·
Apr 22

Alkermes reports sustained Phase 2 alixorexton benefits in narcolepsy type 1 study

Reuters
·
Apr 16

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients With Narcolepsy Type 1 at the American Academy of Neurology (Aan) 2026 Annual Meeting

THOMSON REUTERS
·
Apr 16

Alkermes announces publication of 56-week post hoc analysis of Lybalvi

TIPRANKS
·
Apr 14

Alkermes says 56-week analysis links Lybalvi to improved schizophrenia negative symptoms

Reuters
·
Apr 14

Findings From Long-Term Analysis of the Effects of Lybalvi® (Olanzapine and Samidorphan) on Negative Symptoms of Schizophrenia Published in the Journal of Clinical Psychiatry

THOMSON REUTERS
·
Apr 14

Alkermes Plc : Mizuho Raises Target Price to $53 From $45

THOMSON REUTERS
·
Apr 10

Analysts Offer Insights on Healthcare Companies: Wuxi Biologics (Cayman) (OtherWXIBF) and Alkermes (ALKS)

TIPRANKS
·
Apr 10

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

BofA Adjusts Price Target on Alkermes Public to $36 From $34, Maintains Neutral Rating

MT Newswires Live
·
Apr 09

Alkermes EVP, CLO David Joseph Gaffin disposes of USD 70,309 in shares

Reuters
·
Apr 07